B-Cell Non-Hodgkin Lymphoma — Trials

B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,757
Recruiting: 905
Ph III recruiting: 103
Growth YoY: +3.6%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (954)

clinicaltrialsPublishedShowing 151–200 of 1,961 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06762431	Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.(VTB-CLL002)	recruiting	Phase 1 / Phase 2	24	Vitebsk Regional Clinical Cancer CentreOTHER	1	Aug 13, 2026	clinicaltrials
NCT06980116	Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies	recruiting	Phase 1	85	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.